Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Corifact Market Revenue Outlook: What CAGR Is Expected Through 2030?
The expansion observed during the historic period was driven by the increased identification of fibrinogen deficiency, progress in trauma care, standardized protocols for managing surgical bleeding, regulatory approvals for plasma-derived treatments, and the integration of these therapies into hospital practices.
The projected expansion during the forecast period is driven by a rise in emergency surgical procedures, the requirements of an aging demographic, the broadening of trauma center capabilities, advancements in coagulation testing, and a growing need for fast-acting hemostatic products. Key developments shaping this period involve the growing application of fibrinogen concentrates, a heightened emphasis on swift hemorrhage management, the widening scope of trauma and surgical services, the implementation of hospital-focused hemostasis control programs, and increased usage in the management of liver disorders.
Download A Free Sample Report For Comprehensive Market Insights:
Corifact Market Opportunity Drivers: What Is Creating New Revenue Potential?
The growing occurrence of bleeding disorders is anticipated to drive forward expansion within the corifact market. Such disorders hinder the blood’s capacity to clot effectively, resulting in extended or excessive bleeding episodes. This uptick in bleeding conditions stems from enhanced diagnostic capabilities, broader public awareness, progress in genetic screening, shifts in lifestyle habits, and the presence of underlying health issues. Corifact addresses factor XIII deficiency-related bleeding disorders by supplying the absent clotting factor, enabling the formation of stable clots and minimizing excessive blood loss. As reported in December 2023 by the United Kingdom Haemophilia Centre Doctors’ Organisation—a UK entity—the 2023/24 data underscores the bleeding disorder burden, listing 6,835 people with haemophilia A, 1,378 with haemophilia B, 1,845 carriers of haemophilia A, 892 women with factor VIII deficiency, and 390 carriers of haemophilia B. Consequently, the escalating prevalence of these disorders fuels growth in the corifact market.
Growing consumer interest in biological products is set to stimulate progress in the corifract market moving forward. These products are intricate pharmaceutical agents sourced from living organisms, employed for diagnosing, preventing, treating, or curing diseases and medical conditions. Heightened demand for them results from increasing environmental consciousness, more informed consumer choices, and a push for sustainable, effective alternatives to synthetic compounds. Corifract enhances biological products by improving their stability, absorption, and effectiveness, guaranteeing optimal results and extended usability via creative formulation and delivery methods. According to an August 2025 report from the Assistant Secretary for Planning and Evaluation—a US government agency—biosimilar net revenue can range from a USD 33.5 million loss in small markets to USD 9.5 billion in large ones, while proposed changes like universal interchangeability, a global comparator, and removing comparative efficacy studies could reduce development costs by USD 2 billion, raise lifetime revenues by USD 13.5 million, and add USD 84 million, respectively. Thus, rising demand for biological products propels the corifract market.
A higher volume of surgical interventions is forecasted to accelerate growth in the corifact market. These procedures involve medical operations carried out by clinicians to address injuries, diseases, or abnormalities via manual or instrument-based techniques. The increase in surgeries is largely driven by an aging population needing care for age-linked conditions and progress in minimally invasive technologies, which enhance safety and accessibility. Corifact is utilized during surgeries to manage and stop excessive bleeding in patients with congenital Factor XIII deficiency, aiding clot stabilization and wound healing. As reported in June 2024 by the American Society of Plastic Surgeons—a US professional organization—minimally invasive procedures grew 7 percent in 2023, outpacing surgical ones by 2 percent, with neuromodulator injections and hyaluronic acid fillers reaching over 9 million and 5 million treatments each. Therefore, the expanding number of surgical procedures supports corifact market expansion.
Corifact Market Segment Analysis Highlighting Growth Areas
The corifact market covered in this report is segmented –
1) By Product: Human-Derived Factor XIII, Recombinant Factor XII
2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management
3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics
Corifact Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the corifact market are CSL Behring
Access The Complete Corifact Market Report:
Corifact Market Geographic Distribution And Regional Opportunities
North America was the largest region in the corifact market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model